AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Zura Bio Limited
Video analysis: ZURA
All videosNo video analysis for this stock yet. Request one from our team.
News: ZURA
Zura Bio to Participate in the Cantor Global Healthcare Conference
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that members of its management team will participate in the following upcoming investor conference: Cantor Global Healthcare Conference Location: New York, NY Fireside chat: Wednesday, September 9, 2026, at 9.
Contrasting Zura Bio (NASDAQ:ZURA) and Soligenix (NASDAQ:SNGX)
Soligenix (NASDAQ: SNGX - Get Free Report) and Zura Bio (NASDAQ: ZURA - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, analyst recommendations and valuation. Profitability This table compares Soligenix and Zura Bio's
Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today reported that on August 20, 2026, the Company granted inducement awards consisting of options to purchase up to 587,000 Class A Ordinary Shares (the “Options”) to thirteen newly hired employees. These.
Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
Zura Bio Limited (Nasdaq: ZURA) (âZuraâ), a clinicalâstage biotechnology company developing novel and differentiated medicines to meaningfully improve the
Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical‑stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced financial results for the second quarter ended June 30, 2026, and provided recent corporate updates. “The second quarter was marked by strong execution across our tibulizumab programs, with enrollment now com.
Zura Bio Limited (NASDAQ:ZURA) Receives $10.75 Average Target Price from Brokerages
Shares of Zura Bio Limited (NASDAQ: ZURA - Get Free Report) have received an average rating of "Moderate Buy" from the seven research firms that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, four have issued a buy rating and
Zura Bio (NASDAQ:ZURA) Trading 5.3% Higher – Here’s Why
Zura Bio Limited (NASDAQ: ZURA - Get Free Report)'s share price rose 5.3% during trading on Friday. The company traded as high as $5.52 and last traded at $5.5280. 150,021 shares were traded during trading, a decline of 82% from the average daily volume of 851,443 shares. The stock had previously closed at $5.25. Wall
Analyst Sees Multi-Billion-Dollar Sales Potential for Zura Bio's Lead Therapy
On Wednesday, William Blair initiated coverage of Zura Bio Limited (NASDAQ:ZURA) with an Outperform rating, citing the potential of its lead candidate, tibulizumab, to deliver differentiated efficacy across severe autoimmune diseases.
Similar companies
-
Assembly Biosciences, Inc.
ASMB
·
NASDAQ
Compare
-
Foghorn Therapeutics Inc.
FHTX
·
NASDAQ
Compare
-
Immuneering Corporation
IMRX
·
NASDAQ
Compare
-
Sagimet Biosciences Inc.
SGMT
·
NASDAQ
Compare
-
Nautilus Biotechnolgy, Inc.
NAUT
·
NASDAQ
Compare
-
Aardvark Therapeutics, Inc. Common Stock
AARD
·
NASDAQ
Compare